May 31, 2022 (CAMBRIDGE, MA) – The Massachusetts Biotechnology Council (MassBio®) today opened the application for the second cohort of its biotech accelerator, MassBioDrive. Scientists and early-stage startups with high potential, transformative therapeutic pipelines, or platform technologies are invited to apply for the Fall 2022 program by July 1, 2022 at 12:00PM (noon) ET.
“We look forward to exposing a new cohort of emerging biotechs to the business-focused curriculum and expert mentors at the center of the MassBioDrive accelerator,” said Gauri Nair, Vice President of Innovation Services at MassBio. “Through MassBio’s expansive and global life sciences network, selected founders will gain the knowledge and make the connections to take their enterprise outside the lab.”
The Fall 2022 accelerator will run from September 26 to November 23. MassBioDrive provides emerging biotechs from around the world with a market-focused launchpad of training, resources, and networks in their growth trajectory to fully realize the potential of their science – at no cost and with no equity taken. During a high impact, eight-week hybrid program, startups selected through a rigorous two-step vetting process will experience:
- Participate in six business-focused curriculum modules taught by seasoned experts from J.P. Morgan, KPMG, Marsh McLennan, Thermo Fisher Scientific, Wilson Sonsini Goodrich & Rosati, and Xontogeny;
- Partner with a small, dedicated group of industry mentors;
- Connect with MassBio’s global life sciences network through ecosystem-wide events and targeted 1:1 partnering opportunities; and
- After presenting at a Demo Day, receive a stipend award from Bristol Myers Squibb and access to potential resources from and/or connections to MassBioDrive partners including Evaluate, Johnson & Johnson Innovation, MassChallenge, Springer Nature, and Watershed Informatics.
Held biannually, MassBioDrive’s Fall 2022 program builds on the success of the inaugural Spring cohort, which included five startups from three countries and two U.S. states.
“MassBio’s programming continues to deliver the skills, training, and resources that prepare emerging companies and talented scientists for the next step in their journey,” said Joe Boncore, CEO of MassBio. “Through MassBioDrive, we can give early-stage startups that are focusing on unmet medical needs an opportunity to be successful on the business side to advance their breakthrough science.”
“The breadth of the science and technologies being explored by the innovative companies who were a part of MassBioDrive’s spring cohort makes me enthusiastic for what will come in as we begin accepting applications from new entrepreneurs,” said Kendalle Burlin O’Connell, President & COO of MassBio. “The Massachusetts’ life sciences ecosystem is only as strong as the pipeline of patient-driven, early-stage companies, and this program is one way that MassBio is actively seeding the ecosystem with promising companies.”